Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation • First randomized controlled clinical trial to evaluate VX1-guided ablation compared to conventional anatomical ablation approaches to treat persistent atrial fibrillation• International,...

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in improving...

Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication Volta VX1 decision support software reproduces expert-physician electrogram (EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent...

Volta Medical VX1 AI Software to be Featured at Heart Rhythm 2022 -  Company’s VX1 AI software for use in atrial fibrillation will be featured during several events at the Congress - MARSEILLE, France and PROVIDENCE, R.I., April 27, 2022 (GLOBE NEWSWIRE) -- Volta...

First U.S. patients with persistent cardiac arrythmias treated using Volta Medical’s artificial intelligence-based analysis Novel, FDA-cleared and CE-certified medical device is designed to help cardiologists identify cardiac abnormalities in patients undergoing ablation treatment for persistent, drug-resistant atrial...